非残疾患者抗凝相关脑出血的临床结局与神经影像特征
这项前瞻性12个月观察研究在15家三级卒中中心纳入196例病前改良Rankin量表评分<2的急性非创伤性抗凝相关脑出血患者,比较非维生素K口服抗凝药(NOAC)与维生素K拮抗剂(VKA)相关脑出血的影像与临床结局。NOAC组基线血肿体积更小、重度神经功能缺损更少、显著血肿扩大更少;NOAC预处理独立关联更小基线血肿体积及更低的重度神经功能缺损几率。
要点
- NOAC相关脑出血患者基线血肿体积中位数低于VKA相关患者(13.8 vs 19.5 mL,P=0.026)。
- NOAC组入院时美国国立卫生研究院卒中量表评分>10分的比例低于VKA组(37% vs 55.3%,P=0.025)。
- VKA组显著血肿扩大比例高于NOAC组(37.4% vs 17%,P=0.008)。
核心结论
- 与VKA相关脑出血相比,NOAC相关脑出血患者基线血肿体积更小,重度神经功能缺损的几率更低。
研究设计与样本
- 前瞻性12个月观察研究,在美国、欧洲和亚洲的15家三级卒中中心开展。
- 连续纳入病前改良Rankin量表评分<2的急性非创伤性抗凝相关脑出血患者,按抗凝药类型分为NOAC组与VKA组。
- 共196例,NOAC相关62例(平均年龄75.0±11.4岁,男性54.8%),VKA相关134例(平均年龄72.3±10.5岁,男性73.1%)。
主要发现
- NOAC组基线血肿体积中位数低于VKA组(13.8 [2.5-37.6] mL vs 19.5 [6.6-52.0] mL,P=0.026)。
- NOAC组入院时NIHSS评分>10分的比例低于VKA组(37% vs 55.3%,P=0.025)。
- VKA组显著血肿扩大比例高于NOAC组(37.4% vs 17%,P=0.008)。
- NOAC预处理独立关联更小基线血肿体积(标准化线性回归系数:-0.415 [95% CI,-0.780至-0.051]),并因此降低重度神经功能缺损几率(比值比0.44;95% CI,0.22-0.85)。
临床怎么用
- 作者认为这些发现对临床医生选择抗凝治疗具有重要参考价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- The aim of this study was to prospectively validate our prior findings of smaller hematoma volume and lesser neurological deficit in nonvitamin K oral anticoagulant (NOAC) compared with Vitamin K antagonist (VKA)-related intracerebral hemorrhage (ICH). Methods- Prospective 12-month observational study in 15 tertiary stroke centers in the United States, Europe, and Asia. Consecutive patients with premorbid modified Rankin Scale score of <2 with acute nontraumatic anticoagulant-related ICH divided into 2 groups according to the type of anticoagulant: NOAC versus VKA. We recorded baseline ICH volume, significant hematoma expansion (absolute [12.5 mL] or relative [>33%] increase), neurological severity measured by National Institutes of Health Stroke Scale score, 90-day mortality, and functional status (modified Rankin Scale score). Results- Our cohort comprised 196 patients, 62 NOAC related (mean age, 75.0±11.4 years; 54.8% men) and 134 VKA related (mean age, 72.3±10.5; 73.1% men). There were no differences in vascular comorbidities, antiplatelet, and statin use; NOAC-related ICH patients had lower median baseline hematoma volume (13.8 [2.5-37.6] versus 19.5 [6.6-52.0] mL; P=0.026) and were less likely to have severe neurological deficits (National Institutes of Health Stroke Scale score of >10 points) on admission (37% versus 55.3%, P=0.025). VKA-ICH were more likely to have significant hematoma expansion (37.4% versus 17%, P=0.008). NOAC pretreatment was independently associated with smaller baseline hematoma volume (standardized linear regression coefficient:-0.415 [95% CI, -0.780 to -0.051]) resulting in lower likelihood of severe neurological deficit (odds ratio, 0.44; 95% CI, 0.22-0.85) in multivariable-adjusted models. Conclusions- Patients with NOAC-related ICH have smaller baseline hematoma volumes and lower odds of severe neurological deficit compared with VKA-related ICH. These findings are important for practicing clinicians making anticoagulation choices.
引用
- Lioutas VA, Goyal N, Katsanos AH, et al. Clinical Outcomes and Neuroimaging Profiles in Nondisabled Patients With Anticoagulant-Related Intracerebral Hemorrhage. Stroke. 2018. PMID: 30355114. doi:10.1161/STROKEAHA.118.021979
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。